Compare DexCom, Inc. (DXCM) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Zscaler Inc — how do they compare? DexCom, Inc. trades at $77.68 (market cap $28.06B), while Zscaler Inc trades at $146.78 (market cap $23.96B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | ZS | |
|---|---|---|
Market Cap | $28.06B | $23.96B |
Sector | Health | Technology |
52-Week High | $89.53 | $336.27 |
52-Week Low | $54.84 | $118.05 |
Enterprise Value | $27.03B | $22.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Zscaler (ZS) trades at $152.09, up 7.24% with strong technical momentum and bullish moving averages. The stock shows improving fundamentals with revenue growing from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -2.44% net margin. Recent earnings beats and 79% analyst buy ratings support optimism, but the stock faces class action investigations and AI infrastructure cost pressures.
ZS presents a growth opportunity in cybersecurity with Zero Trust adoption tailwinds, but profitability challenges and legal risks warrant caution. The consensus price target of $192.64 suggests 27% upside potential, though investors must weigh strong revenue growth against persistent losses and competitive pressures in the evolving AI security landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
